Title Physician

Phase 2 Trial of Voyager V1 in Combination With Cemiplimab in Cancer Patients

NCT ID : 04291105
Phase : 2
Location : Santa Monica, CA
Dr. O'Day

⁸⁹Zr-Df-IAB22M2C (CD8 PET Tracer) for PET/CT in Patients With Metastatic Solid Tumors

NCT ID : 03802123
Phase : 2
Location : Santa Monica, CA
Dr. O'Day

Study of Cabozantinib in Combination With Atezolizumab to Subjects With Locally Advanced or Metastatic Solid Tumors

NCT ID : 03170960
Phase : 1 and 2
Location : Santa Monica, CA
Dr. Twardowski

Study of Olaparib Plus Pembrolizumab Versus Chemotherapy Plus Pembrolizumab After Induction With First-Line Chemotherapy Plus Pembrolizumab in Triple Negative Breast Cancer (TNBC) (MK-7339-009/KEYLYNK-009)

NCT ID : 4191135
Phase : 2 and 3
Location : Santa Monica, CA
Dr. O'Day

A Randomized Phase III Clinical Trial Evaluating Post-Mastectomy Chestwall and Regional Nodal XRT and Post-Lumpectomy Regional Nodal XRT in Patients with Positive Axillary Nodes Before Neoadjuvant Chemotherapy Who Convert to Pathologically Negative Axillary Nodes After Neoadjuvant Chemotherapy

NCT ID : 01872975
Location : Burbank, CA
Dr. Sanghani

Clinical Implementation of a Polygenic Risk Score (PRS) for Breast Cancer

NCT ID : 03688204
Protocol Number : SNP-17-001
Location : Burbank, CA
Dr. Gordon and Dr. Grumley

A Phase I Study of AGEN1181, an Fe-Engineered Anti-CTLA-4 Monoclonal Antibody as Monotherapy and in Combination with AGEN2034, an Anti-PD-1 Monoclonal Antibody, in Subjects with Advanced Cancer

NCT ID : 03860272
Protocol Number : C-800-01
Phase : 1
Location : Santa Monica, CA
Dr. O'Day

A Randomized, Open-Label, Phase 2 Study of Nivolumab in Combination With Ipilimumab or Nivolumab Monotherapy in Participants With Advanced or Metastatic Solid Tumors of High Tumor Mutational Burden (TMB-H)

NCT ID : NCT03668119
Protocol Number : CA209-848
Phase : 2
Location : Santa Monica, CA
Dr. O'Day

Intratumoral AST-008 Combined With Pembrolizumab in Patients With Advanced Solid Tumors

NCT ID : 03684785
Protocol Number : AST-008-102
Phase : 1b/2
Location : Santa Monica, CA
Dr. O'Day

Safety, Tolerability, Immunogenicity, and Antitumor Activity of GEN-009 Adjuvanted Vaccine

NCT ID : 03633110
Protocol Number : GEN-009-101
Phase : 1 and 2
Location : Santa Monica, CA
Dr. Twardowski